Evolving data on risk and current screening recommendations for colorectal cancer in cystic fibrosis: Pre‐ and posttransplant
Pediatric Pulmonology · 2024
DOI: 10.1002/ppul.27060 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pediatric Pulmonology, 2024. Verfasst von Zain Raza und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Gastroenterology & Hepatology, Saint Louis University School of Medicine, Saint Louis, Missouri, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Colorectal Neoplasms, Early Detection of Cancer, Cystic Fibrosis Transmembrane Conductance Regulator. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: None.
Abstract (Originalsprache)
Advances in treatment for cystic fibrosis (CF), including cystic fibrosis transmembrane conductor regulator (CFTR) modulators, have ushered in an era where patients with CF have much longer life expectancies. This shift in life expectancy demands increased attention to diseases of aging in patients with CF. A notable complication of CF is early‐onset colorectal cancer (CRC), which is especially prevalent in patients with severe mutations and after transplant. CFTR acts as a tumor suppressor gene based on knockout models. Lack of CFTR expression promotes carcinogenic processes such as intestinal inflammation and deleterious gut microbiome changes. The consensus Cystic Fibrosis Foundation recommendations advocate treating this population as a high‐risk group, using a colonoscopy‐only screening strategy starting at age 40 in patients without transplant and at age 30 after transplant. Screening should be considered every 5 years if negative and every 3 years or sooner for patients with adenomatous polyps. Future research will determine the role of noninvasive CRC screening tools in this population, as well as the effects of CFTR modulators on the risk of developing CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Gastroenterology & Hepatology, Saint Louis University School of Medicine, Saint Louis, Missouri, USA.
- Department of Medicine, Division of Gastroenterology and Liver Disease, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
- Department of Medicine, Case Western Reserve University, School of Medicine, Cleveland, Ohio, USA.
ORCID-Profile: Linda C Cummings
Förderung
- None
Zitieren
APA
Raza, Z., Islam, B. N., Hachem, C. Y., & Cummings, L. C. (2024). Evolving data on risk and current screening recommendations for colorectal cancer in cystic fibrosis: Pre‐ and posttransplant. Pediatric Pulmonology. https://doi.org/10.1002/ppul.27060
Vancouver
Raza Z, Islam BN, Hachem CY, Cummings LC. Evolving data on risk and current screening recommendations for colorectal cancer in cystic fibrosis: Pre‐ and posttransplant. Pediatric Pulmonology. 2024. doi:10.1002/ppul.27060
BibTeX
@article{Raza2024,
author = {Raza, Zain and Islam, Bianca N and Hachem, Christine Y and Cummings, Linda C},
title = {Evolving data on risk and current screening recommendations for colorectal cancer in cystic fibrosis: Pre‐ and posttransplant},
journal = {Pediatric Pulmonology},
year = {2024},
doi = {10.1002/ppul.27060}
}
EUVIMED